Cargando…

Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course

BACKGROUND: Mainly severe (CTCAE grade 3–4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common and could affect therapy management. The aim of this study was to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Vries–Huizing, Daphne M. V., Versleijen, Michelle W. J., Sinaasappel, Michiel, Walraven, Iris, Geluk–Jonker, Martine M., Tesselaar, Margot E. T., Hendrikx, Jeroen J. M. A., de Wit–van der Veen, Berlinda J., Stokkel, Marcel P. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601524/ https://www.ncbi.nlm.nih.gov/pubmed/34793530 http://dx.doi.org/10.1371/journal.pone.0260073

Ejemplares similares

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
por: Huizing, Daphne Merel Valerie, et al.
Publicado: (2018)

(177)Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Multicentre quantitative (68)Ga PET/CT performance harmonisation
por: Huizing, Daphne M. V., et al.
Publicado: (2019)

Post-PRRT scans: which scans to make and what to look for
por: Aalbersberg, Else A., et al.
Publicado: (2022)

Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
por: Siebinga, Hinke, et al.
Publicado: (2022)

Early differences in dynamic uptake of (68)Ga-PSMA-11 in primary prostate cancer: A test-retest study
por: olde Heuvel, J., et al.
Publicado: (2021)

Effect of renal function on pemetrexed-induced haematotoxicity
por: Ando, Yosuke, et al.
Publicado: (2016)

Benzene induces haematotoxicity by promoting deacetylation and autophagy
por: Qian, Shanhu, et al.
Publicado: (2018)

Predicting [(177)Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [(68)Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)
por: Aalbersberg, Else A., et al.
Publicado: (2020)

Predicting the effect of different folate doses on [(68)Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

Day-to-day variability of [(68)Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions
por: van der Veen, Berlinda J., et al.
Publicado: (2012)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Bone marrow impairment during early [(177)Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
por: Kind, Felix, et al.
Publicado: (2022)

The consequences of a new software package for the quantification of gated-SPECT myocardial perfusion studies
por: van der Veen, Berlinda J., et al.
Publicado: (2010)

Quality control of [(177)Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery
por: Aalbersberg, Else A., et al.
Publicado: (2022)

Role of steroid on management of limb swelling and local pain in haematotoxic snake bite
por: Ghosh, Manas, et al.
Publicado: (2022)

Individual modelling of haematotoxicity with NARX neural networks: A knowledge transfer approach()()()()
por: Steinacker, Marie, et al.
Publicado: (2023)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Examination of Haematotoxicity of Fixed-Dose Highly Active Antiretroviral Drug in Albino Wistar Rats
por: Nubila, Thomas, et al.
Publicado: (2012)

Haematotoxic effects of methanolic extract of Boswellia sacra oleo gum resin (frankinccense) in rats
por: Alyahya, AbdulRahman A I, et al.
Publicado: (2021)

A physiologically based pharmacokinetic model for [(68)Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
por: Siebinga, Hinke, et al.
Publicado: (2023)

Somatostatin receptor saturation after administration of high peptide amounts of [(177)Lu]Lu-HA-DOTATATE: when enough is enough
por: Siebinga, Hinke, et al.
Publicado: (2022)

Targeted Radionuclide Therapy
por: Ersahin, Devrim, et al.
Publicado: (2011)

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy
por: Ebbers, Sander C., et al.
Publicado: (2022)

Update on radionuclide therapy in oncology
por: Nitipir, Cornelia, et al.
Publicado: (2017)

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of (68)Ga-DOTATATE in patients without neuroendocrine tumors
por: Siebinga, H., et al.
Publicado: (2021)

Ventricular dyssynchrony assessed by gated myocardial perfusion SPECT using a geometrical approach: a feasibility study
por: van der Veen, Berlinda J., et al.
Publicado: (2011)

Targeting Melanin in Melanoma with Radionuclide Therapy
por: Allen, Kevin J. H., et al.
Publicado: (2022)

Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”
por: Brans, B., et al.
Publicado: (2007)

What is the Role of the Bystander Response in Radionuclide Therapies?
por: Brady, Darren, et al.
Publicado: (2013)

(68)Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Radionuclide therapy of hepatocellular carcinoma
por: Sundram, FX
Publicado: (2006)

Nephrotoxicity after radionuclide therapies
por: Parihar, Ashwin Singh, et al.
Publicado: (2021)

Release of patients after therapy with unsealed radionuclides
por: Commission Internationale de Protection contre les Radiations
Publicado: (2004)

Mitigation of Benzene-Induced Haematotoxicity in Sprague Dawley Rats through Plant-Extract-Loaded Silica Nanobeads
por: Rehan, Touseef, et al.
Publicado: (2023)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4c4cml2l9v3lg51so660eoiirg